Pairing Doxorubicin with Natural Products May Offer Some Cardiac Protection

Adam G Alani, PhD Assistant Professor of Pharmaceutics Department of Pharmaceutical Sciences College of Pharmacy Oregon State University-Oregon Health & Science University Affiliate Assistant Professor Department of Biomedical Engineering School of Medicine at Oregon Health & Science University Oregon State University-Portland Campus at OHSU Portland Oregon 97201-5042 MedicalResearch.com Interview with:
Adam G Alani, PhD
Assistant Professor of Pharmaceutics
Department of Pharmaceutical Sciences
College of Pharmacy
University Affiliate Assistant Professor
Department of Biomedical Engineering
School of Medicine at Oregon Health & Science University Oregon State University-Portland Campus at OHSU Portland Oregon

Medical Research: What is the background for this study? What are the main findings?

Dr. Alani: Doxorubicin, a potent anticancer agent is being under-utilized in the clinic due to its life threatening cardiotoxicity.  This cardiotoxicity has imposed a life dose limit of 450 -550 mg/m2 which restricts clinicians use of this drug for subsequent relapses when a patient has responded to the drug favorably in the past.  In our lab, we are looking to pair this drug with natural products that have shown both cardioprotective effects and while enhancing the potency of common chemotherapeutics like doxorubicin.  Using this complementary approach with a high dose of doxorubicin known to cause cardiotoxicity, we have fully/ partially mitigated this cardiotoxicity in healthy mice. The goal is not to change the dosing regimen for doxorubicin, but to pair it with our nanoscale drug delivery systems containing these natural products as complementary therapy.

Medical Research: What should clinicians and patients take away from your report?

Dr. Alani: That by pairing doxorubicin with these natural products we may be able to extend that life dose limit for doxorubicin.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Alani: Future studies are underway to test our nanoscale formulation with doxorubicin in ovarian cancer mouse models to determine the long term ability of this therapeutic approach in mitigating doxorubicin induced cardiotoxicity while maintaining or improving its potency against tumor tissues.  This will help establish the level of cardioprotection possible with this treatment regimen and provide an indication of where the higher doxorubicin dose limit may lie when complemented with these natural products. Upon successful completion of this phase we will move to testing in larger animal model systems.

Citation:

J Control Release. 2015 Jul 6;213:128-133. doi: 10.1016/j.jconrel.2015.06.040. [Epub ahead of print]

Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo.

Cote B1, Carlson LJ2, Rao DA3, Alani AW4.

[wysija_form id=”3″]

Adam G Alani, PhD (2015). Pairing Doxorubicin with Natural Products May Offer Some Cardiac Protection 

Tags: